ID

33113

Description

Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00971659

Lien

https://clinicaltrials.gov/show/NCT00971659

Mots-clés

Versions (1)
  1. 28/11/2018 28/11/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

28 novembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Type 2 Diabetes NCT00971659

Anglais

Eligibility Type 2 Diabetes NCT00971659

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female subjects aged between 35 and 70 years, inclusive
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
type 2 diabetes with duration >6 months and <10 years
Description

Non-Insulin-Dependent Diabetes Mellitus Duration

Type de données

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0449238
for at least 3 months: treatment solely with a long- or intermediate-acting insulin formulation (insulin glargine, insulin detemir, or nph insulin) with or without a stable dose of metformin or treatment solely with a stable dose of metformin or combination of stable doses of metformin plus sulfonylureas
Description

Insulin, Long-Acting | Intermediate-acting insulin | Insulin Glargine | Insulin detemir | Insulin, isophane | Metformin Dose Stable | Sulfonylureas Dose Stable | Combined Modality Therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0304870
UMLS CUI [2]
C0304869
UMLS CUI [3]
C0907402
UMLS CUI [4]
C0537270
UMLS CUI [5]
C0021658
UMLS CUI [6,1]
C0025598
UMLS CUI [6,2]
C0178602
UMLS CUI [6,3]
C0205360
UMLS CUI [7,1]
C0038766
UMLS CUI [7,2]
C0178602
UMLS CUI [7,3]
C0205360
UMLS CUI [8]
C0009429
hba1c >=7.0% and <=10.0%
Description

Hemoglobin A1c measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0474680
if treated with antihypertensive or lipid lowering agents, the treatment regimen had to be stable during 3 months prior to study start
Description

Antihypertensive Agents Stable | Hypolipidemic Agents Stable

Type de données

boolean

Alias
UMLS CUI [1,1]
C0003364
UMLS CUI [1,2]
C0205360
UMLS CUI [2,1]
C0086440
UMLS CUI [2,2]
C0205360
written informed consent
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
history or presence of cancer or any clinically relevant diseases
Description

Malignant Neoplasms | Disease Relevance Clinical

Type de données

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C2347946
UMLS CUI [2,3]
C0205210
chronic heart failure nyha class iii or iv, unstable angina pectoris or myocardial infarction within the previous 6 months
Description

Chronic heart failure New York Heart Association Classification | Angina, Unstable | Myocardial Infarction

Type de données

boolean

Alias
UMLS CUI [1,1]
C0264716
UMLS CUI [1,2]
C1275491
UMLS CUI [2]
C0002965
UMLS CUI [3]
C0027051
recurrent hypoglycemia
Description

Recurrent hypoglycemia

Type de données

boolean

Alias
UMLS CUI [1]
C1846288
abnormal lab tests at screening (alat and/or asat >=3 times uln), creatinine >1.6 mg/dl in males and >1.4 mg/dl in females
Description

Laboratory test result abnormal | Alanine aminotransferase increased | Aspartate aminotransferase increased | Creatinine measurement, serum | Gender

Type de données

boolean

Alias
UMLS CUI [1]
C0438215
UMLS CUI [2]
C0151905
UMLS CUI [3]
C0151904
UMLS CUI [4]
C0201976
UMLS CUI [5]
C0079399
clinically relevant ecg findings at screening
Description

ECG finding Relevance Clinical

Type de données

boolean

Alias
UMLS CUI [1,1]
C0438154
UMLS CUI [1,2]
C2347946
UMLS CUI [1,3]
C0205210
treatment with a rapid-acting insulin or with a mixed insulin formulation during the previous 3 months
Description

Insulin, Short-Acting | Insulin Formulation Mixed

Type de données

boolean

Alias
UMLS CUI [1]
C0356365
UMLS CUI [2,1]
C0021641
UMLS CUI [2,2]
C0524527
UMLS CUI [2,3]
C0205430
treatment with any other oha than metformin or metformin plus sulfonylureas during the previous 3 months
Description

Oral hypoglycemic | Exception Metformin | Exception Sulfonylureas

Type de données

boolean

Alias
UMLS CUI [1]
C0359086
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0025598
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0038766
any systemic or topical treatment with drugs known to influence glucose metabolism
Description

Systemic therapy | Topical administration of treatment | Pharmaceutical Preparations Influence Glucose metabolism

Type de données

boolean

Alias
UMLS CUI [1]
C1515119
UMLS CUI [2]
C0001566
UMLS CUI [3,1]
C0013227
UMLS CUI [3,2]
C4054723
UMLS CUI [3,3]
C0596620
Retour au début de la page

Similar models

Eligibility Type 2 Diabetes NCT00971659

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
male or female subjects aged between 35 and 70 years, inclusive
boolean
C0001779 (UMLS CUI [1])
Non-Insulin-Dependent Diabetes Mellitus Duration
Item
type 2 diabetes with duration >6 months and <10 years
boolean
C0011860 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Insulin, Long-Acting | Intermediate-acting insulin | Insulin Glargine | Insulin detemir | Insulin, isophane | Metformin Dose Stable | Sulfonylureas Dose Stable | Combined Modality Therapy
Item
for at least 3 months: treatment solely with a long- or intermediate-acting insulin formulation (insulin glargine, insulin detemir, or nph insulin) with or without a stable dose of metformin or treatment solely with a stable dose of metformin or combination of stable doses of metformin plus sulfonylureas
boolean
C0304870 (UMLS CUI [1])
C0304869 (UMLS CUI [2])
C0907402 (UMLS CUI [3])
C0537270 (UMLS CUI [4])
C0021658 (UMLS CUI [5])
C0025598 (UMLS CUI [6,1])
C0178602 (UMLS CUI [6,2])
C0205360 (UMLS CUI [6,3])
C0038766 (UMLS CUI [7,1])
C0178602 (UMLS CUI [7,2])
C0205360 (UMLS CUI [7,3])
C0009429 (UMLS CUI [8])
Hemoglobin A1c measurement
Item
hba1c >=7.0% and <=10.0%
boolean
C0474680 (UMLS CUI [1])
Antihypertensive Agents Stable | Hypolipidemic Agents Stable
Item
if treated with antihypertensive or lipid lowering agents, the treatment regimen had to be stable during 3 months prior to study start
boolean
C0003364 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0086440 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Malignant Neoplasms | Disease Relevance Clinical
Item
history or presence of cancer or any clinically relevant diseases
boolean
C0006826 (UMLS CUI [1])
C0012634 (UMLS CUI [2,1])
C2347946 (UMLS CUI [2,2])
C0205210 (UMLS CUI [2,3])
Chronic heart failure New York Heart Association Classification | Angina, Unstable | Myocardial Infarction
Item
chronic heart failure nyha class iii or iv, unstable angina pectoris or myocardial infarction within the previous 6 months
boolean
C0264716 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
C0002965 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
Recurrent hypoglycemia
Item
recurrent hypoglycemia
boolean
C1846288 (UMLS CUI [1])
Laboratory test result abnormal | Alanine aminotransferase increased | Aspartate aminotransferase increased | Creatinine measurement, serum | Gender
Item
abnormal lab tests at screening (alat and/or asat >=3 times uln), creatinine >1.6 mg/dl in males and >1.4 mg/dl in females
boolean
C0438215 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
C0151904 (UMLS CUI [3])
C0201976 (UMLS CUI [4])
C0079399 (UMLS CUI [5])
ECG finding Relevance Clinical
Item
clinically relevant ecg findings at screening
boolean
C0438154 (UMLS CUI [1,1])
C2347946 (UMLS CUI [1,2])
C0205210 (UMLS CUI [1,3])
Insulin, Short-Acting | Insulin Formulation Mixed
Item
treatment with a rapid-acting insulin or with a mixed insulin formulation during the previous 3 months
boolean
C0356365 (UMLS CUI [1])
C0021641 (UMLS CUI [2,1])
C0524527 (UMLS CUI [2,2])
C0205430 (UMLS CUI [2,3])
Oral hypoglycemic | Exception Metformin | Exception Sulfonylureas
Item
treatment with any other oha than metformin or metformin plus sulfonylureas during the previous 3 months
boolean
C0359086 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0038766 (UMLS CUI [3,2])
Systemic therapy | Topical administration of treatment | Pharmaceutical Preparations Influence Glucose metabolism
Item
any systemic or topical treatment with drugs known to influence glucose metabolism
boolean
C1515119 (UMLS CUI [1])
C0001566 (UMLS CUI [2])
C0013227 (UMLS CUI [3,1])
C4054723 (UMLS CUI [3,2])
C0596620 (UMLS CUI [3,3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial